findmyKOL

Frank Fossella, MD

Basic profile

The University of Texas MD Anderson Cancer Center

ORCIDNone on fileNPI
RegionHouston, TX · South CentralSpecialtyMedical OncologyFocusOncology
Last active 2023findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2023Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Frank Fossella is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 313 publications with 20,666 citations (h-index 63).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
313publications

Distinct works indexed by OpenAlex.

20,666citations

Total citations across indexed works.

63h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
8companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

8 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    28%
    Serotonin-3 Receptor Antagonist10.2%
    Ondansetron Hcl100%
    Part D38 patients
    Corticosteroid7.3%
    Prednisone100%
    Part D26 patients

    + 3 more classes in this area

  • Cancer & immunology

    24.3%
    Kinase inhibitor21.9%
    Tagrisso76%Erlotinib Hcl8%Iressa8%Lenvima8%
    Part D<11 patients
    Other antineoplastic agents2.4%
    Lumakras100%
    Part D<11 patients
  • Nervous system

    20.2%
    Opioid Agonist11.2%
    Morphine Sulfate Er47%Morphine Sulfate20%Hydromorphone Hcl19%Tramadol Hcl15%
    Part D<11 patients
    gamma-Aminobutyric Acid A Receptor Positive Modulator3.7%
    Zolpidem Tartrate100%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”